


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A compound of Formula (I):



Formula (I)

wherein:

B is thiazole heteroarylene; ~~wherein heteroarylene is selected from an aromatic monocyclic ring having five members of which at least one member is a N, O or S atom and which optionally contains one additional N atom;~~

A and E are independently phenylene or pyridinylene;

t is an integer from 1 to 4;

$R_1$  is selected from hydrogen,  $C_{1-8}$ alkyl,  $C_{1-8}$ alkoxy,  $NH_2$ ,  $NH(C_{1-8}alkyl)$ ,  $N(C_{1-8}alkyl)_2$ , halogen or hydroxy; wherein  $R_1$  is substituted on the 3, 4 or 5 position of the "A" ring;

$R_2$  and  $R_3$  are independently selected from hydrogen,  $C_{1-8}alkyl$ - $R_4$  or  $C_{3-6}cycloalkyl$ ;


$R_4$  is selected from  $(C_{1-8}alkoxy)$ ,  $NH_2$ ,  $NH(C_{1-8}alkyl)$ ,  $N(C_{1-8}alkyl)_2$ ,  $(halo)_{1-3}$ , hydroxy,  $C_{3-6}cycloalkyl$ - $R_5$ , heterocycl- $R_5$ , aryl- $R_5$  or heteroaryl- $R_5$ ; and,

R<sub>5</sub> is 1 to 2 substituents selected from hydrogen, C<sub>1-8</sub>alkyl or (C<sub>1-8</sub>)alkoxy  
(wherein alkoxy is substituted on a carbon atom);

and pharmaceutically acceptable salts thereof.

2. (canceled)
3. (canceled)
4. The compound of claim 1 wherein t is an integer from 1 to 2.
5. The compound of claim 1 wherein t is an integer 1.
6. The compound of claim 1 wherein R<sub>1</sub> is selected from hydrogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, NH<sub>2</sub>, NH(C<sub>1-4</sub>alkyl), N(C<sub>1-4</sub>alkyl)<sub>2</sub>, halogen or hydroxy; wherein R<sub>1</sub> is substituted on the 3, 4 or 5 position of the "A" ring.
7. The compound of claim 1 wherein R<sub>1</sub> is selected from hydrogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy or halogen; wherein R<sub>1</sub> is substituted on the 4 position of the "A" ring.
8. The compound of claim 1 wherein R<sub>2</sub> and R<sub>3</sub> are independently selected from hydrogen, C<sub>1-4</sub>alkyl-R<sub>4</sub> or C<sub>3-6</sub>cycloalkyl.
9. The compound of claim 1 wherein R<sub>4</sub> is selected from C<sub>1-4</sub>alkoxy, NH<sub>2</sub>, NH(C<sub>1-4</sub>alkyl), N(C<sub>1-4</sub>alkyl)<sub>2</sub>, (halo)<sub>1-3</sub>, hydroxy, C<sub>3-6</sub>cycloalkyl-R<sub>5</sub>, heterocyclyl-R<sub>5</sub>, aryl-R<sub>5</sub> or heteroaryl-R<sub>5</sub>.
10. The compound of claim 1 wherein R<sub>4</sub> is selected from heterocyclyl-R<sub>5</sub> or heteroaryl-R<sub>5</sub>.

11. The compound of claim 1 wherein  $R_4$  is selected from pyrrolidinyl- $R_5$ , morpholinyl- $R_5$ , furyl- $R_5$  or indolyl- $R_5$ .
12. The compound of claim 1 wherein  $R_5$  is 1 to 2 substituents selected from hydrogen,  $C_{1-4}$ alkyl or  $(C_{1-4})$ alkoxy (wherein alkoxy is substituted on a carbon atom).
13. The compound of claim 1 wherein the compound of Formula (I) is selected from a compound of Formula (Ia):



Formula (Ia)

wherein  $R_1$ , position "a" and  $R_3$  are dependently selected from:

$R_1$	a		$R_3$
Cl,	3	and	n-propyl;
Cl,	4	and	n-propyl;
Cl,	3	and	isobutyl;
Cl,	3	and	cyclopentyl;
Cl,	3	and	cyclohexyl;
Cl,	3	and	cyclopropyl;
Cl,	3	and	$CH_2$ -(1-Me)-2-pyrrolidinyl;
Cl,	3	and	$(CH_2)_2$ -4-morpholinyl;
Cl,	3	and	(5-Me)furfuryl;
Cl,	3	and	$(CH_2)_2$ -(5-OMe)-1 <i>H</i> -indol-3-yl;
Cl,	4	and	cyclopentyl;
or			
Cl,	3	and	H.

14. (withdrawn) A method for treating or ameliorating a reactive oxygen

species mediated inflammatory disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

15. (withdrawn) The method of claim 14 wherein the reactive oxygen species is selected from a superoxide, hydrogen peroxide, hydroxyl radical or HOCl reactive oxygen species.
16. (withdrawn) The method of claim 14 wherein the reactive oxygen species mediated inflammatory disorder is selected from a phosphorylation mediated disorder, a polymorphonuclear leucocyte mediated disorder, a macrophage mediated disorder, a lipopolysaccharide mediated disorder, a tumor necrosis factor- $\alpha$  mediated disorder, a cytokine IFN- $\gamma$  mediated disorder, an interleukin-2 mediated disorder, inflammatory arthritis, potassium peroxochromate arthritis, rheumatoid arthritis, osteoarthritis or Alzheimer's disease.
17. (withdrawn) The method of claim 14 wherein the therapeutically effective amount of the compound of claim 1 is from about 0.001 mg/kg/day to about 1000 mg/kg/day.